PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF ARQ 087, A NOVEL PAN-FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING INTRAHEPATIC CHOLAN-GIOCARCINOMA.

被引：0
|
作者：
Savage, R. [1 ]
Trinh, M. [2 ]
Dupuis, M. [2 ]
Marier, J. F. [2 ]
Schwartz, B. [1 ]
机构：
[1] ArQule, Burlington, MA USA
[2] Certara Strateg Consulting, Montreal, PQ, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-091
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [21] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Garmezy, B.
    Borad, M.
    Lin, C. C.
    Chen, L. T.
    Perez, C. A.
    Kato, S.
    Tam, B.
    Severson, P.
    Quah, C. S.
    Harding, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
  • [22] A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors
    Rowinsky, EK
    Pacey, S
    Patnaik, A
    O'Donnell, A
    Mita, MM
    Atadja, P
    Peng, B
    Dugan, M
    Scott, JW
    De Bono, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 200S - 200S
  • [23] A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
    Soria, J. C.
    Gan, H. K.
    Blagden, S. P.
    Plummer, R.
    Arkenau, H. T.
    Ranson, M.
    Evans, T. R. J.
    Zalcman, G.
    Bahleda, R.
    Hollebecque, A.
    Lemech, C.
    Dean, E.
    Brown, J.
    Gibson, D.
    Peddareddigari, V.
    Murray, S.
    Nebot, N.
    Mazumdar, J.
    Swartz, L.
    Auger, K. R.
    Fleming, R. A.
    Singh, R.
    Millward, M.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2268 - 2274
  • [24] First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma
    Saleh, M.
    Papadpoulos, K.
    Arabnia, A.
    Patnaik, A.
    Stein, R. M.
    Chai, F.
    Lamar, M.
    Savage, R.
    Abbadessa, G.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 104 - 104
  • [25] First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts.
    Saleh, Mansoor
    Papadopoulos, Kyri
    Arabnia, Alireza
    Patnaik, Amita
    Stein, Robin M.
    Cattaneo, Federica
    Abbadessa, Giovanni
    Greenberg, Jonathan
    Warren, Stephen
    Tolcher, Anthony
    CANCER RESEARCH, 2013, 73 (08)
  • [26] Phase I pharmacokinetic, and pharmacodynamic trial of the novel oral notch inhibitor MK-0752 in patients with advanced breast cancer and other solid tumors.
    Krop, I. E.
    Kosh, M.
    Fearen, I
    Savoie, J.
    Dallob, A.
    Stone, J.
    Winer, E.
    Freedman, S. J.
    LoRusso, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S287 - S287
  • [27] First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors
    Soria, J. C.
    De Braud, F.
    Cereda, R.
    Bahleda, R.
    Delmonte, A.
    Angevin, E.
    Varga, A.
    Noberasco, C.
    Dall'O', E.
    Lassau, N.
    Dromain, C.
    Bellomi, M.
    Farace, F.
    Bertolini, F.
    Zucchetti, M.
    Marsoni, S.
    Camboni, M. G.
    ANNALS OF ONCOLOGY, 2011, 22 : 40 - 40
  • [28] FIRST-IN-MAN STUDY OF E-3810, A NOVEL VEGFR AND FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Soria, J. C.
    Dienstmann, R.
    de Braud, F.
    Cereda, R.
    Bahleda, R.
    Hollebecque, A.
    Tabernero, J.
    Delmonte, A.
    Dromain, C.
    Lassau, N.
    Farace, F.
    Zucchetti, M.
    Marsoni, S.
    Camboni, M. G.
    ANNALS OF ONCOLOGY, 2012, 23 : 16 - 17
  • [29] Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma
    Tolcher, A.
    Harb, W.
    Sachdev, J.
    Papadopoulos, K.
    Bordoni, R.
    Chai, F.
    Larmar, M.
    Savage, R.
    Abbadessa, G.
    Saleh, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S66 - S66
  • [30] A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors
    Mackay, HJ
    Hoekstra, R
    Eskens, FALM
    Loos, WJ
    Crawford, D
    Voi, M
    Van Vreckem, A
    Evans, TRJ
    Verweij, J
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2636 - 2644
12345